Tango Therapeutics (TNGX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $22.04, -2.91% vs the prior close of $22.70.
- Volume 3.69M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TNGX dips 2.9% to $22.04. Closed at $22.04, -2.91% vs the prior close of $22.70. Day range $21.82–$23.17, opened at $23.12.
TNGX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — TNGX dips 2.9% to $22.04
- Closed at $22.04, -2.91% vs the prior close of $22.70. Day range $21.82–$23.17, opened at $23.12.
- Volume was 3.69M shares, 1.3x its 50-day average of 2.95M.
- Price is -8.0% vs its 50-day average ($23.96) and +1.8% vs its 200-day average ($21.65).
- 52-week range $6.69–$34.39; today's close sits at 55% of that range, 35.9% below the 52-week high.
Oct 15, 2026 — TNGX rises 2.3% to $22.70
- Closed at $22.70, +2.30% vs the prior close of $22.19. Day range $21.78–$22.96, opened at $22.26.
- Volume was 2.90M shares, 1.0x its 50-day average of 2.93M.
- Price is -5.8% vs its 50-day average ($24.10) and +5.2% vs its 200-day average ($21.59).
- 52-week range $6.69–$34.39; today's close sits at 58% of that range, 34.0% below the 52-week high.
Oct 14, 2026 — TNGX ends flat (-0.1%) to $22.19
- Closed at $22.19, -0.14% vs the prior close of $22.22. Day range $21.52–$23.02, opened at $21.98.
- Volume was 3.44M shares, 1.2x its 50-day average of 2.89M.
- Price is -8.4% vs its 50-day average ($24.22) and +3.1% vs its 200-day average ($21.52).
- 52-week range $6.69–$34.39; today's close sits at 56% of that range, 35.5% below the 52-week high.
Oct 13, 2026 — TNGX slides 8.1% to $22.22 on 3.5x normal volume
- Closed at $22.22, -8.07% vs the prior close of $24.17. Day range $21.85–$24.11, opened at $23.85.
- Volume was 9.62M shares, 3.5x its 50-day average of 2.74M — unusually heavy trading.
- Price is -8.8% vs its 50-day average ($24.36) and +3.6% vs its 200-day average ($21.45).
- 52-week range $6.69–$34.39; today's close sits at 56% of that range, 35.4% below the 52-week high.
Oct 12, 2026 — TNGX rises 1.5% to $24.17, 3 up days in a row
- Closed at $24.17, +1.51% vs the prior close of $23.81. Day range $23.34–$24.47, opened at $23.57.
- Volume was 2.87M shares, 1.1x its 50-day average of 2.72M.
- Price is -1.2% vs its 50-day average ($24.46) and +13.0% vs its 200-day average ($21.38).
- 52-week range $6.69–$34.39; today's close sits at 63% of that range, 29.7% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — TNGX jumps 5.5% to $23.81
- Closed at $23.81, +5.49% vs the prior close of $22.57. Day range $22.44–$24.12, opened at $22.60.
- Volume was 3.10M shares, 1.2x its 50-day average of 2.68M.
- Price is -2.9% vs its 50-day average ($24.52) and +11.8% vs its 200-day average ($21.30).
- 52-week range $6.69–$34.39; today's close sits at 62% of that range, 30.8% below the 52-week high.
Oct 8, 2026 — TNGX jumps 3.4% to $22.57 on 1.9x normal volume
- Closed at $22.57, +3.39% vs the prior close of $21.83. Day range $20.98–$22.68, opened at $21.57.
- Volume was 5.07M shares, 1.9x its 50-day average of 2.63M — unusually heavy trading.
- Price is -8.2% vs its 50-day average ($24.60) and +6.3% vs its 200-day average ($21.23).
- 52-week range $6.69–$34.39; today's close sits at 57% of that range, 34.4% below the 52-week high.
Oct 7, 2026 — TNGX dips 0.3% to $21.83, 5 down days in a row
- Closed at $21.83, -0.32% vs the prior close of $21.90. Day range $21.38–$22.46, opened at $21.64.
- Volume was 3.39M shares, 1.3x its 50-day average of 2.69M.
- Price is -11.5% vs its 50-day average ($24.67) and +3.2% vs its 200-day average ($21.16).
- 52-week range $6.69–$34.39; today's close sits at 55% of that range, 36.5% below the 52-week high.
- That makes 5 straight losses.
Oct 6, 2026 — TNGX slides 5.1% to $21.90, 4 down days in a row
- Closed at $21.90, -5.11% vs the prior close of $23.08. Day range $21.36–$23.16, opened at $23.16.
- Volume was 4.35M shares, 1.6x its 50-day average of 2.65M.
- Price is -11.6% vs its 50-day average ($24.76) and +3.8% vs its 200-day average ($21.09).
- 52-week range $6.69–$34.39; today's close sits at 55% of that range, 36.3% below the 52-week high.
- That makes 4 straight losses.
Oct 5, 2026 — TNGX dips 0.7% to $23.08, 3 down days in a row
- Closed at $23.08, -0.69% vs the prior close of $23.24. Day range $22.25–$23.56, opened at $23.29.
- Volume was 1.94M shares, 0.7x its 50-day average of 2.66M.
- Price is -7.2% vs its 50-day average ($24.86) and +9.8% vs its 200-day average ($21.02).
- 52-week range $6.69–$34.39; today's close sits at 59% of that range, 32.9% below the 52-week high.
- That makes 3 straight losses.
Oct 2, 2026 — TNGX slides 4.9% to $23.24 on 2.0x normal volume
- Closed at $23.24, -4.95% vs the prior close of $24.45. Day range $23.09–$25.09, opened at $25.09.
- Volume was 5.25M shares, 2.0x its 50-day average of 2.58M — unusually heavy trading.
- Price is -6.8% vs its 50-day average ($24.93) and +10.9% vs its 200-day average ($20.95).
- 52-week range $6.69–$34.39; today's close sits at 60% of that range, 32.4% below the 52-week high.
TNGX latest news & SEC filings
Every SEC filing by or about TNGX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Crystal Adam converted options/RSUs into 27,000 shares at $5.20 (≈$140.40K) on Oct 1, 2026; now holds 142,743
- Crystal Adam sold 26,400 shares at $24.45 (≈$645.60K) on Oct 1, 2026; now holds 116,343
- Crystal Adam sold 600 shares at $25.32 (≈$15.19K) on Oct 1, 2026; now holds 115,743
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Newcomb Jessica sold 700 shares at $22.80 (≈$15.96K) on Sep 22, 2026; now holds 66,621
- Newcomb Jessica sold 5,100 shares at $23.97 (≈$122.24K) on Sep 22, 2026; now holds 61,521
- Newcomb Jessica sold 2,400 shares at $25.17 (≈$60.41K) on Sep 22, 2026; now holds 59,121
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 22, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Crystal Adam sold 27,000 shares at $22.37 (≈$603.99K) on Sep 1, 2026
- Crystal Adam sold 27,000 shares at $22.37 (≈$603.99K) on Sep 1, 2026
- Crystal Adam sold 27,000 shares at $22.37 (≈$603.99K) on Sep 1, 2026
- Crystal Adam sold 27,000 shares at $22.37 (≈$603.99K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 11, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $3.18M) (-100.0% vs Jun 30, 2025)
- Net income: -$55.34M (prior year -$38.85M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.37 (prior year -$0.35) (loss widened vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K/A — Current report (amended)
Amended current report
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade TNGX
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 5, 2026, Jan 8, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.26% (largest 14.3%). That is a volatile stock.
- Liquidity: about 3.88M shares (≈$85.55M) trade per day on average.
- 52-week position: $22.04 vs a range of $6.69–$34.39 (55% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Jessica Newcomb sold 2,400 shares on Sep 22, 2026.
- Latest filings: 8-K Aug 11, 2026; 8-K Aug 11, 2026; 10-Q Aug 11, 2026.
- Share count: 168.61M shares outstanding (Aug 4, 2026), +51.5% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TNGX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 23.12 | 23.17 | 21.82 | 22.04 | 3.69M |
| Oct 15, 2026 | 22.26 | 22.96 | 21.78 | 22.70 | 2.90M |
| Oct 14, 2026 | 21.98 | 23.02 | 21.52 | 22.19 | 3.44M |
| Oct 13, 2026 | 23.85 | 24.11 | 21.85 | 22.22 | 9.62M |
| Oct 12, 2026 | 23.57 | 24.47 | 23.34 | 24.17 | 2.87M |
| Oct 9, 2026 | 22.60 | 24.12 | 22.44 | 23.81 | 3.10M |
| Oct 8, 2026 | 21.57 | 22.68 | 20.98 | 22.57 | 5.07M |
| Oct 7, 2026 | 21.64 | 22.46 | 21.38 | 21.83 | 3.39M |
| Oct 6, 2026 | 23.16 | 23.16 | 21.36 | 21.90 | 4.35M |
| Oct 5, 2026 | 23.29 | 23.56 | 22.25 | 23.08 | 1.94M |
| Oct 2, 2026 | 25.09 | 25.09 | 23.09 | 23.24 | 5.25M |
| Oct 1, 2026 | 24.90 | 25.43 | 23.95 | 24.45 | 2.91M |
| Sep 30, 2026 | 24.64 | 25.41 | 23.82 | 24.95 | 3.66M |
| Sep 29, 2026 | 24.32 | 24.80 | 23.18 | 24.42 | 2.99M |
| Sep 28, 2026 | 24.92 | 24.92 | 23.70 | 24.30 | 2.41M |
| Sep 25, 2026 | 24.95 | 25.38 | 24.08 | 24.92 | 3.25M |
| Sep 24, 2026 | 23.99 | 24.83 | 23.50 | 24.63 | 2.29M |
| Sep 23, 2026 | 25.40 | 25.92 | 24.06 | 24.45 | 4.96M |
| Sep 22, 2026 | 22.33 | 25.75 | 22.25 | 25.53 | 6.97M |
| Sep 21, 2026 | 21.90 | 22.74 | 21.63 | 22.33 | 2.56M |
About Tango Therapeutics
Tango Therapeutics (TNGX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BOSTON, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1819133.
TNGX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert Azelby | Director | Jun 23, 2026 |
| Lesley Ann Calhoun | Director | Jun 8, 2026 |
| John B Ketchum | Director | Jun 8, 2026 |
| Sung Lee | Director | Jun 8, 2026 |
| Malte Peters | President & CEO | Jan 12, 2026 |
| Mace Rothenberg | Director | Jun 8, 2026 |
| Barbara Weber | Director, Executive Chair | Feb 4, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Daniella Beckman | Chief Financial Officer | Feb 4, 2026 |
| Adam Crystal | President, R&D | Sep 3, 2026 |
| Matthew Gall | Chief Financial Officer | May 5, 2026 |
| Jessica Newcomb | Principal Accounting Officer | Sep 24, 2026 |
| Malte Peters | President & CEO | Jan 12, 2026 |
| Barbara Weber | Director, Executive Chair | Feb 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | Jessica Newcomb | Sale | 2,400 | $25.17 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 5,100 | $23.97 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 700 | $22.80 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 2,400 | $25.17 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 5,100 | $23.97 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 700 | $22.80 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 2,400 | $25.17 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 5,100 | $23.97 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 700 | $22.80 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 2,400 | $25.17 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 5,100 | $23.97 |
| Sep 22, 2026 | Jessica Newcomb | Sale | 700 | $22.80 |
| Sep 1, 2026 | Adam Crystal | Sale | 27,000 | $22.37 |
| Sep 1, 2026 | Adam Crystal | Sale | 27,000 | $22.37 |
| Sep 1, 2026 | Adam Crystal | Sale | 27,000 | $22.37 |
TNGX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $62.38M | $-101.59M | -0.87 | $-138.89M |
| Dec 31, 2024 | $42.07M | $-130.30M | -1.19 | $-131.50M |
| Dec 31, 2023 | $36.53M | $-101.74M | -1.08 | $-117.98M |
| Dec 31, 2022 | $24.86M | $-108.18M | -1.23 | $-109.08M |
| Dec 31, 2021 | $37.04M | $-58.23M | -0.94 | $-59.53M |
Latest balance sheet: total assets $1.07B, total liabilities $49.35M, cash $345.56M (as of Jun 30, 2026).
TNGX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $26.34 |
| May 13, 2026 | 8-K Item 2.02 (results) | $25.51 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $16.83 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $11.06 |
| Nov 4, 2025 | 8-K Item 2.02 (results) | $8.01 |
| Oct 23, 2025 | 8-K Item 2.02 (results) | $7.53 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $6.91 |
| May 12, 2025 | 8-K Item 2.02 (results) | $1.31 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $2.18 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $2.86 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $3.24 |
| Aug 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on TNGX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.